Immunotherapy related myocarditis, colitis, uveitis, or pneumonitis. No prior immunotherapy for advanced/metastatic MCC Prior treatment with immunotherapy Immunotherapy Prior immunotherapy is allowed. Participants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy. Concurrent immunotherapy is allowed Immunotherapy less than or equal to weeks prior to registration Prior immunotherapy including sipuleucel-T Previous use of investigational agents, chemotherapy or immunotherapy for lymphoma any time prior to enrollment (i.e. must have untreated disease); prior allogeneic or autologous transplants are also not allowed Prior treatment with any immunotherapy Must have completely recovered or recovered to baseline prior to screening from any prior AEs occurring while receiving prior immunotherapy. Received chemotherapy/immunotherapy in the last weeks For post immunotherapy patients with NSCLC all of the following apply: For other post immunotherapy patients all of the following must apply: Actively receiving chemo-immunotherapy History of active immunotherapy in the previous month. Phase II only: patients with colorectal cancer with known microsatellite instability (MSI)-high disease who have previously been treated with immunotherapy or who have refused treatment with immunotherapy Patients who have received any prior immunotherapy Patients that have undergone Tyrosinase immunotherapy Immunotherapy-naive. Subjects who have received prior PSA, MUC, and/or brachyury-targeted immunotherapy (e.g. vaccine) are eligible for this trial if this treatment was discontinued at least months prior to enrollment Prior treatment with adenovirus-based vectors immunotherapy Cohort #: received only frontline CD-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy for patients with DLBCL; monotherapy rituximab or other CD-directed immunotherapy prior to frontline chemotherapy, as maintenance therapy, and radiotherapy in a limited field or as a part of the frontline treatment plan are permitted; last treatment dose should be weeks before start of study treatment Chemotherapy or immunotherapy within weeks prior to start of huF History of prior immunotherapy within the last years (immunotherapy allowed for lead-in cohort in castration resistant disease) Patients with prior salvage chemo-immunotherapy, radiation therapy, autologous transplantation are included Prior immunotherapy including sipuleucel-T Chemotherapy or immunotherapy =< days prior to registration Patients may have had no more than one prior line of chemotherapy or immunotherapy in the metastatic setting; at least days must have elapsed from the last chemo/immunotherapy administration until the start of protocol treatment, and patients must have recovered from the side effects of any of these agents Received systemic treatment for cancer, including immunotherapy, within days prior to initiation of conditioning chemotherapy administration within this protocol Patients may have received prior immunotherapy Prior chemotherapy or immunotherapy will be allowed if new or persistent measurable site(s) of disease are present Prior immunotherapy or chemotherapy is allowed as long as > days prior to enrollment Chemotherapy, biochemotherapy, radiation or immunotherapy or any investigational treatment within days prior to receiving any study drug. Any prior systemic anti-cancer immunotherapy treatment Chemotherapy or immunotherapy within weeks prior to the first dose of vaccine Prior chemotherapy, radiation, sipuleucel-T or other experimental immunotherapy less than weeks prior to the start of study medication. Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol Ongoing systemic therapy for prostate cancer including, but not limited to:\r\n\t* Immunotherapy (e.g. sipuleucel-T, ipilimumab)\r\n\t* Non-protocol prescribed chemotherapy (e.g. cabazitaxel) Be within months (+/- week) between last dose of an immunotherapy agent and study enrollment\r\n* Patients may continue with maintenance immunotherapy as part of standard of care therapy while receiving radiation No prior chemotherapy, targeted therapy, or immunotherapy for mesothelioma Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study). No restriction based on prior treatments but at least weeks from prior immunotherapy, or prior investigational agents No prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatment Have received biologic therapy, including immunotherapy, < days prior to CD; Immunotherapy (e.g. tumor vaccine) (At least days since last dose of immunotherapy agent(s) prior to first dose of tazemetostat) Previous use of indoximod or tergenpumatucel-L immunotherapy. Patients that have previously progressed on immunotherapy such as ipilimumab will be eligible Previous chemotherapy/immunotherapy within weeks before study entry Chemotherapy, biologics, immunotherapy, vaccine, cytokine therapy within weeks prior to enrollment Previous treatment with surgery, radiation, chemotherapy, immunotherapy or any targeted agents are allowed provided that: \r\n* Chemotherapy was administered > days before the start of HD IL-\r\n* Surgery, radiation, immunotherapy or any targeted agents was administered > days before the start of HD IL- Patients who have received prior immunotherapy No chemotherapy or immunotherapy for a minimum of three weeks prior to start of huF Prior neurologic toxicity to previous immunotherapy Those receiving prior immunotherapy must meet all of the following conditions: Patients who have received prior immunotherapy Prior treatment with other immunotherapy, including antibodies, is allowed >= weeks between completion of chemotherapy or immunotherapy and first (st) vaccination Subjects who have received prior immunotherapy may be eligible Patients must have received previous systemic therapy to include: a regimen of chemotherapy, immunotherapy including anti-PDL or anti-PD-L therapies, combined chemotherapy and immunotherapy, provided treatment was discontinued >= weeks prior to initiation of treatment on the present protocol Systemic chemotherapy or immunotherapy within days of enrollment; Any prior immunotherapy or vaccine therapy Antibodies or immunotherapy within weeks before the first dose of study treatment. Prior immunotherapy Prior investigational immunotherapy Immunotherapy (e.g., tumor vaccine) At least weeks since last dose of immunotherapy agent(s) prior to first dose of tazemetostat) Received only frontline CD-directed immunotherapy with anthracycline- or anthracenedione-based multi-agent chemotherapy. Monotherapy rituximab or other CD-directed immunotherapy as maintenance therapy prior to frontline chemotherapy, and radiotherapy in a limited field or as part of the frontline treatment plan are permitted. Prior platinum chemotherapy or immunotherapy Treatment with immunotherapy against PCa within the previous months prior to randomization Previous immunotherapy History of listeriosis or previous treatment with a listeria-based immunotherapy More than one chemotherapeutic regimen given for R/M disease. Prior treatment with immunotherapy is allowed. Prior treatment with other next generation anti-androgens or other CYP inhibitors, immunotherapy or radiopharmaceutical agents for prostate cancer EXCLUSION FOR TREATMENT: Prior neurologic toxicity to previous immunotherapy Prior immunotherapy with CRS- or any other Listeria-based agent, therapeutic cancer vaccine, or adoptive T cell immunotherapy Prior immunotherapy will be permitted; however, any prior immunotherapy must be discontinued at least weeks before peptide vaccine administration; non-immunologic therapy may be continued Received systemic treatment for cancer, including immunotherapy, within one month prior to initiation of dosing within this protocol Prior chemotherapy, immunotherapy, or targeted therapy is allowed as long as it did not include dasatinib Immunotherapy [mAbs, Interferons, Cytokines (except GCSF)] Subjects who have received prior CEA, MUC, and/or brachyury-targeted immunotherapy (vaccine) are eligible for this trial if this treatment was discontinued at least weeks prior to enrollment Participation in any other immunotherapy treatment, that in the opinion of the principal investigator would be unsafe to receive further checkpoint blockade immunotherapy. History of prior immunotherapy within the last years Prior systemic cytotoxic chemotherapies and/or novel immunotherapy treatments for MCC are allowed. A wash-out period of weeks prior to aNK treatment will be required. The patient must not have received any immunotherapy for their brain tumor Immunotherapy within the days prior to randomization Any immunotherapy within weeks of first dose of study drug. Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents < days of the first dose of study treatment. Most recent targeted therapy < days of the first dose of study treatment. Received any other therapeutic investigational agent within days of screening, except for immunotherapy. Patients with previous immunotherapy are not eligible regardless of timing. Any immunotherapy within weeks of first dose of study drug. Willingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy and biologic therapy at least weeks prior to the start of RT. Immunotherapy within days prior to signing consent Nave untreated patients or patients who have progressed on or after prior first line immunotherapy for resectable locally advanced or metastatic melanoma; prior adjuvant therapy is permitted (e.g. IFN, IL- therapy, any other immunotherapy, radiotherapy or chemotherapy), except the administration of BRAF or MEK inhibitors Any previous systemic chemotherapy treatment, extensive radiotherapy or investigational agent other than immunotherapy, or patients who have received more than one line of immunotherapy for locally advanced unresectable or metastatic melanoma; Ipilimumab (adjuvant) or other immunotherapy treatment must have ended at least weeks prior to randomization History of prior immunotherapy within the last years Treatment with an immunotherapy within days Prior sipuleucel-T treatment or investigational immunotherapy. Patients with washout period < weeks from the last dose of ipilimumab or other immunotherapy. No chemotherapy or immunotherapy for a minimum of three weeks prior to study enrollment Previous immunotherapy treatment for metastatic disease in the preceding months; Note: immunotherapy in the adjuvant setting is allowed ELIGIBILITY PRIOR TO POST-CHEMOTHERAPY IMMUNOTHERAPY: Patients with washout period < weeks from the last dose of ipilimumab or other immunotherapy Prior immunotherapy is allowed Subjects who have received certain prior immunotherapy or had toxicities relating to prior immunotherapy may not be permitted to enroll. o Must not have required the use of additional immunosuppression other than corticosteroids for the management of an adverse event. Immunotherapy =< days prior to pre-registration (e.g. intravesical Bacillus Calmette-Guerin [BCG]) Any previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroids History of any of the following toxicities associated with a prior immunotherapy: Immunotherapy within days prior to randomization Immunotherapy for cancer within weeks of initial study treatment Immunotherapy within days prior to randomization. Patients may have had prior chemotherapy or immunotherapy (vaccines, interferon, ipilimumab, or IL-) with progression or persistent disease Subjects may have received previous courses of an investigational biologic therapy including active or passive immunotherapy greater than days prior to receiving the first injection of DPX-Survivac melanoma: at least prior treatment (including immunotherapy). The participant received prior immunotherapy and is experiencing or has experienced any of the following (OLE cohort only): The participant received prior immunotherapy and at the time of study enrollment, requires steroids or other immunosuppressive agents (OLE cohort only). prior immunotherapy Immunotherapy: ? days after completion of immunotherapy